Claritas Pharmaceuticals, Inc. CLAZF
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.57M | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -770.00K | -- | -- | -- | -- |
| Operating Income | 770.00K | -- | -- | -- | -- |
| Income Before Tax | -4.46M | -- | -- | -- | -- |
| Income Tax Expenses | -420.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.04 | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -680.00K | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.72M | -- | -- | -- | -- |
| EBIT | 770.00K | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -- | -- | -- | -- |
| Normalized Basic EPS | -0.03 | -- | -- | -- | -- |
| EPS Diluted | -0.16 | -- | -- | -- | -- |
| Normalized Diluted EPS | -0.03 | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 123.67M | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 123.67M | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |